<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ateroskleroz</journal-id><journal-title-group><journal-title xml:lang="ru">Атеросклероз</journal-title><trans-title-group xml:lang="en"><trans-title>Ateroscleroz</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-256X</issn><issn pub-type="epub">2949-3633</issn><publisher><publisher-name>НИИТПМ-филиал ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15372/ATER20180301</article-id><article-id custom-type="elpub" pub-id-type="custom">ateroskleroz-75</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>АТЕРОГЕННАЯ НОРМОЛИПИДЕМИЯ У БОЛЬНЫХ С КОРОНАРНЫМ АТЕРОСКЛЕРОЗОМ: ОСОБЕННОСТИ СУБФРАКЦИОННОГО СПЕКТРА АПО-В-СОДЕРЖАЩИХ ЛИПОПРОТЕИНОВ</article-title><trans-title-group xml:lang="en"><trans-title>ATHEROGENIC NORMOLIPIDEMIA IN MEN WITH CORONARY ATHEROSCLEROSIS: SOME PECULIARITIES OF SUBFRACTIONAL DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Озерова</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozerova</surname><given-names>I. N.</given-names></name></name-alternatives><email xlink:type="simple">iozerova@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Метельская</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Metelskaya</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">vmetelskaya@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаврилова</surname><given-names>Н. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Gavrilova</surname><given-names>N. E.</given-names></name></name-alternatives><email xlink:type="simple">ngavrilova@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр профилактической медицины Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Preventive Medicine of Minzdrav of Russia</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>27</day><month>09</month><year>2019</year></pub-date><volume>14</volume><issue>3</issue><fpage>5</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Озерова И.Н., Метельская В.А., Гаврилова Н.Е., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Озерова И.Н., Метельская В.А., Гаврилова Н.Е.</copyright-holder><copyright-holder xml:lang="en">Ozerova I.N., Metelskaya V.A., Gavrilova N.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ateroskleroz.elpub.ru/jour/article/view/75">https://ateroskleroz.elpub.ru/jour/article/view/75</self-uri><abstract><p>Липопротеины низких плотностей (апо-В-содержащие липопротеины) гетерогенны и обладают разной атерогенностью. Цель исследования: провести анализ субфракционного распределения апо-В-содержащих липопротеинов у пациентов с коронарным атеросклерозом при нормолипидемии. Материал и методы: В исследование включены мужчины 30-80 лет с коронарным атеросклерозом, диагностированным коронароангиографией. Субфракционный спектр апо-В-содержащих липопротеинов сыворотки крови определяли с помощью Липопринт-системы (Quantimetrix Lipoprint System, США). Результаты. Среди включенных в исследование больных выделены пациенты с нормолипидемией (уровень ХС Ј Ј 5,0 ммоль/л и ТГ Ј 1,7 ммоль/л) и ХС ЛПНП равен или ниже 2,5 ммоль/л). Пациенты были разделены на две группы по относительному содержанию мелких плотных частиц ЛПНП (ЛПНП 3-4): группа 1 ( n = 16) - мелкие плотные частицы ЛПНП отсутствовали в субфракционном спектре липопротеинов, группа 2 ( n = 22) - эти субфракции присутствовали в спектре. Пациенты обеих групп не различались по уровням общего ХС, ТГ, ХС ЛПНП и апо-АI, а концентрация апо-В и величина отношения апо-В/апо-AI оказались выше во 2-й группе. У пациентов группы 2 обнаружены более низкие доли липопротеинов промежуточной плотности - ЛППП В и ЛППП А и более высокие доли ЛПНП 2. При этом концентрация ХС в субфракции ЛПНП 2 оказалась выше, а концентрация ХС в ЛППП В и ЛППП А ниже. Такой спектр липопротеинов со сдвигом в сторону мелких плотных частиц ЛПНП был ассоциирован с меньшим средним размером ЛПНП частиц (270,7 ± 1,3 Е) по сравнению с теми, у кого мелкие плотные ЛПНП отсутствовали (273,8 ± 0,8 Е). Заключение. У пациентов с коронарным атеросклерозом несмотря на нормолипидемию обнаружено два типа субфракционного распределения апо-В-содержащих липопротеинов. Наличие мелких плотных ЛПНП наряду со сниженным размером частиц ЛПНП свидетельствует, по-видимому, о более высоком атерогенном потенциале.</p></abstract><trans-abstract xml:lang="en"><p>Background: Plasma apo B-containing lipoproteins of low densities represent a heterogeneous population of particles varying by physicochemical composition, functional activity, and atherogenicity. Aim: To study some peculiarities in low density lipoproteins subfractional distribution in men with coronary atherosclerosis at normolipidemia. Material and methods: Patients with angiographically documented coronary atherosclerosis were included into the study ( n = 177; mean age 62.5 ± 9.3 yrs). Lipoprotein subfractional distribution was analyzed using Lipoprint LDL System (Quantimetrix, USA). Results: Out the total cohort normolipidemic patients (total C &lt; 5,0 mmol/l, TG &lt; 1.7 mmol/l, LDL-C &lt; 2.5 mmol/l) with coronary atherosclerosis were selected and thereafter were split into those without small dense LDL (sdLDL) - group 1, n = 16, and and group 2 with presence of sdLDL ( n = 22). Patients from group 2 had lower portion of IDLB: 7.0 ± 1.2 vs 8.5 ± 1.0 %, IDLА: 7.9 ± 1.7 vs 9.6 ± 2.5 %, and higher LDL2 portion: 7.0 ± 2.0 vs 4.3 ± 1.6 %. In group 2 C level in LDL2 was higher than in group 1 while in IDL B it appeared to be lower. Mean LDL particles size in group 2 was lower as well: 270.7 ± 1.3 и 273.8 ± 0.8 Е. Conclusion. In men with coronary atherosclerosis at normolipidemia two different patterns of subfractional distribution of apo B-containing lipoproteins were detected. Presence of sd LDL associated with decreased LDL size could be regarded as more atherogenic profile even at normal lipid levels.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>коронарный атеросклероз</kwd><kwd>нормолипидемия</kwd><kwd>субфракционный спектр</kwd><kwd>ЛПНП Липопринт-система</kwd></kwd-group><kwd-group xml:lang="en"><kwd>coronary atherosclerosis</kwd><kwd>normolipidemia</kwd><kwd>subfractional profile</kwd><kwd>Lipoprint LDL system</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hirayama S., Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease // Clin. Chim. Acta. 2012. Vol. 24, N 414. P. 215-224. DOI:10.1016/j.cca.2012.09.010.</mixed-citation><mixed-citation xml:lang="en">Hirayama S., Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease // Clin. Chim. Acta. 2012. Vol. 24, N 414. P. 215-224. DOI:10.1016/j.cca.2012.09.010.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mora S., Caulfield M.P., Wohlgemuth J. et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial // Circulation. 2015. Vol. 132, N 23. P. 2220-2229. DOI: 10.1161/CIRCULATIONAHA.115.016857.</mixed-citation><mixed-citation xml:lang="en">Mora S., Caulfield M.P., Wohlgemuth J. et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial // Circulation. 2015. Vol. 132, N 23. P. 2220-2229. DOI: 10.1161/CIRCULATIONAHA.115.016857.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lawler P.R., Akinkuolie A.O., Chu A.Y. et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol // J. Am. Heart Assoc. 2017. Vol. 6, N 7. P. e005549. DOI: 10.1161/JAHA.117.005549.</mixed-citation><mixed-citation xml:lang="en">Lawler P.R., Akinkuolie A.O., Chu A.Y. et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol // J. Am. Heart Assoc. 2017. Vol. 6, N 7. P. e005549. DOI: 10.1161/JAHA.117.005549.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dallmeier D., Koening W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA?) and lipoprotein(a) (Lp(a) // Best. Pract. Res. Clin. Endocrnol. Metab. 2014. Vol. 28, N 3. P. 281-294. DOI: 10.1016/j.beem.2014.01.003.</mixed-citation><mixed-citation xml:lang="en">Dallmeier D., Koening W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA?) and lipoprotein(a) (Lp(a) // Best. Pract. Res. Clin. Endocrnol. Metab. 2014. Vol. 28, N 3. P. 281-294. DOI: 10.1016/j.beem.2014.01.003.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sniderman A.D., Williams K., Contois J.H. et al. A meta-analysis of low-demsity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk // Circ. Cardiovasc. Outcomes. 2011. N 4. P. 337-345.</mixed-citation><mixed-citation xml:lang="en">Sniderman A.D., Williams K., Contois J.H. et al. A meta-analysis of low-demsity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk // Circ. Cardiovasc. Outcomes. 2011. N 4. P. 337-345.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity // J. Lipid Res. 2002. Vol. 43, N 9. P. 1363-1379. DOI: 10.1194/jlr. R200004-JLR200September 2002.</mixed-citation><mixed-citation xml:lang="en">Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity // J. Lipid Res. 2002. Vol. 43, N 9. P. 1363-1379. DOI: 10.1194/jlr. R200004-JLR200September 2002.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hoefner D.M., Hodel S.D., O’Brein J.F. et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System // Clin. Chem. 2001. Vol. 47, N 2. P. 266-274.</mixed-citation><mixed-citation xml:lang="en">Hoefner D.M., Hodel S.D., O’Brein J.F. et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System // Clin. Chem. 2001. Vol. 47, N 2. P. 266-274.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Carmena R., Duriez P., Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis // Circulation. 2004. Vol.109. P. III-2-III-7. DOI: org/10.1161/01.CIR.0000131511.50734.44.</mixed-citation><mixed-citation xml:lang="en">Carmena R., Duriez P., Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis // Circulation. 2004. Vol.109. P. III-2-III-7. DOI: org/10.1161/01.CIR.0000131511.50734.44.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Diffenderfer M.R., Schaefer E.J. The composition and metabolism of large and small LDL // Curr. Opin. Lipidol. 2014. Vol. 25, N 3. P. 221-226. DOI: 10.1097/MOL.0000000000000067.</mixed-citation><mixed-citation xml:lang="en">Diffenderfer M.R., Schaefer E.J. The composition and metabolism of large and small LDL // Curr. Opin. Lipidol. 2014. Vol. 25, N 3. P. 221-226. DOI: 10.1097/MOL.0000000000000067.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Srisawasdi P., Vanavanan S., Rochanawutanon M. et al. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations // Clin. Biochem. 2013. Vol. 46, N 15. P. 1509-1515. DOI:10.1016/j.clinbiochem.2013.06.021.</mixed-citation><mixed-citation xml:lang="en">Srisawasdi P., Vanavanan S., Rochanawutanon M. et al. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations // Clin. Biochem. 2013. Vol. 46, N 15. P. 1509-1515. DOI:10.1016/j.clinbiochem.2013.06.021.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Varbo A., Benn M., Nordestgaard B.G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment // Pharmacol. Ther. 2014. Vol. 141, N 3. P. 358-367. DOI: 10.1016/j.pharmthera.2013.11.008.</mixed-citation><mixed-citation xml:lang="en">Varbo A., Benn M., Nordestgaard B.G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment // Pharmacol. Ther. 2014. Vol. 141, N 3. P. 358-367. DOI: 10.1016/j.pharmthera.2013.11.008.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">El Harchaoui K., van der Steeg W.A., Stroes E.S. et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study // J. Am. Coll. Cardiol. 2007. Vol. 49, N 5. P. 547-553. DOI: 10.1016/j.jacc. 2006.09.043.</mixed-citation><mixed-citation xml:lang="en">El Harchaoui K., van der Steeg W.A., Stroes E.S. et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study // J. Am. Coll. Cardiol. 2007. Vol. 49, N 5. P. 547-553. DOI: 10.1016/j.jacc. 2006.09.043.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Рагино Ю.И. Мелкие плотные субфракции липопротеинов низкой плотности и атерогенез // Рос. кардиол. журн. 2004. № 4. С. 84-90.</mixed-citation><mixed-citation xml:lang="en">Рагино Ю.И. Мелкие плотные субфракции липопротеинов низкой плотности и атерогенез // Рос. кардиол. журн. 2004. № 4. С. 84-90.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Озерова И.Н., Перова Н.В., Метельская В.А. и др. Субфракционный спектр липопротеинов низких плотностей при разной степени стенозов коронарных артерий // Кардиоваскулярная терапия и профилактика. 2013. № 4. С. 16-20.</mixed-citation><mixed-citation xml:lang="en">Озерова И.Н., Перова Н.В., Метельская В.А. и др. Субфракционный спектр липопротеинов низких плотностей при разной степени стенозов коронарных артерий // Кардиоваскулярная терапия и профилактика. 2013. № 4. С. 16-20.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Уткина Е.А., Афанасьева О.И., Ежов М.В. и др. Связь различных подфракций липопротеидов с коронарным атеросклерозом у мужчин среднего возраста, получавших терапию статинами // Кардиол. вестн. 2014. Т. 9, № 1. С. 68-76.</mixed-citation><mixed-citation xml:lang="en">Уткина Е.А., Афанасьева О.И., Ежов М.В. и др. Связь различных подфракций липопротеидов с коронарным атеросклерозом у мужчин среднего возраста, получавших терапию статинами // Кардиол. вестн. 2014. Т. 9, № 1. С. 68-76.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Oravec S., Dukat A., Gavornik P. et al. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. is there a need to change our approach to diagnosing dyslipidemia? // Curr. Med. Chem. 2014. Vol. 21, N 25. P. 2892-2901. DOI: 10.2174/0929867321666140303153048.</mixed-citation><mixed-citation xml:lang="en">Oravec S., Dukat A., Gavornik P. et al. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. is there a need to change our approach to diagnosing dyslipidemia? // Curr. Med. Chem. 2014. Vol. 21, N 25. P. 2892-2901. DOI: 10.2174/0929867321666140303153048.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Superko H.R. Advanced lipoprotein testing and subfractionation are clinically useful // Circulation. 2009. Vol. 119, N 17. P. 2383-2395. DOI: 10.1161/CIRCULATIONAHA.108.809582.</mixed-citation><mixed-citation xml:lang="en">Superko H.R. Advanced lipoprotein testing and subfractionation are clinically useful // Circulation. 2009. Vol. 119, N 17. P. 2383-2395. DOI: 10.1161/CIRCULATIONAHA.108.809582.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Davidson M.H. Apolipoprotein measurements: is more widespread use clinically indicated? // Clin. Cardiol. 2009. Vol.32, N 9. P. 482-486. DOI:10.1002/clc.20559.</mixed-citation><mixed-citation xml:lang="en">Davidson M.H. Apolipoprotein measurements: is more widespread use clinically indicated? // Clin. Cardiol. 2009. Vol.32, N 9. P. 482-486. DOI:10.1002/clc.20559.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kucera M., Oravec S., Hirnerova E. et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study // Angiology. 2014. Vol. 65, N 9. P. 794-799. DOI: 10.1177/0003319713507476.</mixed-citation><mixed-citation xml:lang="en">Kucera M., Oravec S., Hirnerova E. et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study // Angiology. 2014. Vol. 65, N 9. P. 794-799. DOI: 10.1177/0003319713507476.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева О.И., Уткина Е.А., Вихрова Е.Б. и др. Наличие мелких плотных липопротеидов низкой плотности в сыворотке крови человека вызывает накопление холестерина моноцитоподобными клетками линии ТНР-1 // Атеросклероз и дислипидемии. 2018. Т. 30, № 1. С. 38-46.</mixed-citation><mixed-citation xml:lang="en">Афанасьева О.И., Уткина Е.А., Вихрова Е.Б. и др. Наличие мелких плотных липопротеидов низкой плотности в сыворотке крови человека вызывает накопление холестерина моноцитоподобными клетками линии ТНР-1 // Атеросклероз и дислипидемии. 2018. Т. 30, № 1. С. 38-46.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
